

- ison of the efficacy of urokinase with streptokinase. *Circulation* 1984; 69: 756-60
37. Mathey DG, Schofer J, Sheehan FH, et al. Intravenous urokinase in acute myocardial infarction. *Am J Cardiol* 1985; 55: 878-82
  38. Neuhaus K-L, Tebbe U, Gottwik M, et al. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German activator urokinase study (GAUS). *J Am Coll Cardiol* 1988; 12: 581-7
  39. De Jaegere PP, Arnold AA, Balk AH, et al. Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. *J Am Coll Cardiol* 1992; 19: 289-94
  40. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. *Lancet* 1993; 342: 1523-28
  41. Hannaford P, Vincent R, Ferry S, et al. Assessment of the practicality and safety of thrombolysis given by general practitioners. *Br J Gen Pract* 1995; 45: 175-9
  42. Adams J, Trent R, Rawles J, on behalf of the GREAT Group. Earliest electrocardiographic evidence of myocardial infarction: implications for thrombolytic treatment. *BMJ* 1993; 307: 409-13
  43. Weston CFM, Penny WJ, Julian DG, on behalf of the British Heart Foundation Working Group. Guidelines for the early management of patients with myocardial infarction. *BMJ* 1994; 308: 767-71
  44. Birkhead JS. Time delays in provision of thrombolytic treatment in six district hospitals. *BMJ* 1992; 305: 445-8
  45. Clinical Resource and Audit Group. Thrombolytic therapy in the early treatment of acute myocardial infarction. Consensus statement. Edinburgh: The Scottish Office, 1991

---

Correspondence and reprints: Dr *John Rawles*, Medicines Assessment Research Unit, University of Aberdeen, Foresterhill, Aberdeen AB9 2ZD, Scotland.

---

## Errata

- Vol. 50, No. 1, page 152:** In section 5, Place of Sulfasalazine in Therapy, the next to last paragraph should read: 'In conclusion, sulfasalazine is an effective DMARD which offers a good trade-off between efficacy and toxicity in the treatment of RA. However, direct comparisons with methotrexate are yet to be conducted. Sulfasalazine may offer a more prompt onset of action . . .'
- [*Rains CP, Noble S, Faulds D. Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995; 50 (1): 137-56*]
- Vol. 50, No. 3, page 434:** In table VI the dosage of ceftriaxone in the studies by Thomas et al. and Niebuhr et al. should read *Ceftriaxone 2g od* (once daily).
- [*Adu A, Armour CL. Drug utilisation review (DUR) of the third generation cephalosporins: focus on ceftriaxone, ceftazidime and cefotaxime. Drugs 1995; 50 (3): 423-9*]